Creative Planning Acquires 180,652 Shares of Amicus Therapeutics, Inc. $FOLD

Creative Planning boosted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 507.1% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 216,279 shares of the biopharmaceutical company’s stock after acquiring an additional 180,652 shares during the quarter. Creative Planning’s holdings in Amicus Therapeutics were worth $1,239,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Strs Ohio bought a new stake in shares of Amicus Therapeutics during the first quarter worth $30,000. PNC Financial Services Group Inc. increased its stake in Amicus Therapeutics by 211.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 3,497 shares during the period. BI Asset Management Fondsmaeglerselskab A S bought a new stake in Amicus Therapeutics during the 1st quarter valued at about $53,000. CWM LLC boosted its position in Amicus Therapeutics by 395.9% in the 2nd quarter. CWM LLC now owns 9,397 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 7,502 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. bought a new position in Amicus Therapeutics in the 2nd quarter worth about $64,000.

Insider Activity

In other Amicus Therapeutics news, insider Ellen Rosenberg sold 36,000 shares of the stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $10.00, for a total transaction of $360,000.00. Following the completion of the sale, the insider directly owned 507,710 shares of the company’s stock, valued at approximately $5,077,100. This represents a 6.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Bradley L. Campbell sold 14,587 shares of Amicus Therapeutics stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $10.04, for a total transaction of $146,453.48. Following the completion of the transaction, the chief executive officer directly owned 1,137,282 shares in the company, valued at approximately $11,418,311.28. The trade was a 1.27% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 201,652 shares of company stock valued at $2,019,288. Company insiders own 2.20% of the company’s stock.

Amicus Therapeutics Stock Down 0.8%

Amicus Therapeutics stock opened at $9.94 on Friday. The company has a quick ratio of 2.29, a current ratio of 3.21 and a debt-to-equity ratio of 1.92. The firm has a market cap of $3.07 billion, a P/E ratio of -82.78 and a beta of 0.66. The business has a fifty day moving average of $8.79 and a two-hundred day moving average of $7.38. Amicus Therapeutics, Inc. has a twelve month low of $5.51 and a twelve month high of $10.57.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.05. The business had revenue of $169.06 million for the quarter, compared to the consensus estimate of $165.24 million. Amicus Therapeutics had a negative return on equity of 5.07% and a negative net margin of 6.67%.The business’s revenue was up 19.5% compared to the same quarter last year. During the same period last year, the business posted $0.10 EPS. Amicus Therapeutics has set its FY 2025 guidance at EPS. On average, analysts forecast that Amicus Therapeutics, Inc. will post 0.15 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on FOLD. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Amicus Therapeutics in a research note on Tuesday. JPMorgan Chase & Co. raised their price objective on Amicus Therapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. Needham & Company LLC raised Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research report on Thursday, September 18th. Zacks Research raised Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. Finally, The Goldman Sachs Group raised their price target on Amicus Therapeutics from $9.00 to $11.00 and gave the company a “neutral” rating in a research note on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Amicus Therapeutics has an average rating of “Moderate Buy” and an average price target of $16.57.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.